Share:

Inactivated Vaccine Market Size, Share, Growth, and Industry Analysis, By Type (Children Inactivated Vaccine and Adult Inactivated Vaccine), By Application (Hospital and Medical Center), and by Regional Forecast to 2035

Last Updated: 15 December 2025
Base Year: 2024
Historical Data: 2022-2024
No of Pages: 81
  • The Inactivated Vaccine Market is expected to reach USD 7065.41 Million by 2035.

  • What CAGR is the Inactivated Vaccine Market expected to exhibit by 2035?

    The Inactivated Vaccine Market is expected to exhibit a CAGR of 3.3% by 2035.

  • What are the driving factors of the Inactivated Vaccine Market?

    The global Inactivated Vaccine Market is propelled by the increasing knowledge of vaccine preventable diseases and immunization programs supported by governments. The growth of the manufacturing technologies and the investments on healthcare increases also boost the market.

  • What was the value of the Inactivated Vaccine Market in 2025?

    In 2025, the Inactivated Vaccine Market value stood at USD 6204.92 Million.

  • Who are some of the prominent players in the Inactivated Vaccine industry?

    Top players in the sector include Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.), Sanofi Pasteur(France), Serum Institute of India Pvt(India).

  • Which region is leading in the Inactivated Vaccine Market?

    North America is currently leading the Inactivated Vaccine Market.